Literature DB >> 18456189

Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.

Marina G Silveira1, Keith D Lindor.   

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456189     DOI: 10.1016/j.cld.2008.02.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

1.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis.

Authors:  Kate M O'Brien; Katryn M Allen; Cheryl E Rockwell; Keara Towery; James P Luyendyk; Bryan L Copple
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

3.  Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation.

Authors:  Gerard Quigley; Mustafa Al Ani; Abdul Nadir
Journal:  Dig Dis Sci       Date:  2018-01-05       Impact factor: 3.199

4.  Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats.

Authors:  Yong-Zhan Zhen; Na-Ren Li; Hong-Wei He; Shuang-Shuang Zhao; Guang-Ling Zhang; Xiao-Fang Hao; Rong-Guang Shao
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

5.  Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice.

Authors:  Heping Yang; Kwangsuk Ko; Meng Xia; Tony W H Li; Pilsoo Oh; Jiaping Li; Shelly C Lu
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

6.  Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis.

Authors:  Ana Lleo; Christopher L Bowlus; Guo-Xiang Yang; Pietro Invernizzi; Mauro Podda; Judy Van de Water; Aftab A Ansari; Ross L Coppel; Howard J Worman; Gregory J Gores; M Eric Gershwin
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 7.  S-adenosylmethionine in liver health, injury, and cancer.

Authors:  Shelly C Lu; José M Mato
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

8.  Innate immunity drives xenobiotic-induced murine autoimmune cholangitis.

Authors:  C-H Chang; Y-C Chen; Y-H Yu; M-H Tao; P S C Leung; A A Ansari; M E Gershwin; Y-H Chuang
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

9.  AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Yun-Ning Chang; Chia-En Loh; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2015-11-01       Impact factor: 7.094

10.  Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice.

Authors:  Heping Yang; Tony W H Li; Yu Zhou; Hui Peng; Ting Liu; Ebrahim Zandi; María Luz Martínez-Chantar; José M Mato; Shelly C Lu
Journal:  Antioxid Redox Signal       Date:  2014-10-17       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.